Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 20;21(1):239.
doi: 10.1186/s12875-020-01312-9.

Evaluation of two family-based intervention programs for children affected by rare disease and their families - research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design

Affiliations

Evaluation of two family-based intervention programs for children affected by rare disease and their families - research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design

Johannes Boettcher et al. BMC Fam Pract. .

Abstract

Background: Families of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families caring for children with rare diseases are known to be at risk for mental disorders, the evaluation of special programs under high methodological standards has not been conducted so far. Moreover, the implementation of interventions for this group into regular care has not yet been accomplished in Germany. The efficacy and cost-effectiveness of a family-based intervention will be assessed.

Methods/design: The study is a 2x2 factorial randomized controlled multicenter trial conducted at 17 study centers throughout Germany. Participants are families with children and adolescents affected by a rare disease aged 0 to 21 years. Families in the face-to-face intervention CARE-FAM, online intervention WEP-CARE or the combination of both will be treated over a period of roughly 6 months. Topics discussed in the interventions include coping, family relations, and social support. Families in the control condition will receive treatment as usual. The primary efficacy outcome is parental mental health, measured by the Structured Clinical Interview for DSM-IV (SCID-I) by blinded external raters. Further outcomes will be assessed from the parents' as well as the children's perspective. Participants are investigated at baseline, 6, 12 and 18 months after randomization. In addition to the assessment of various psychosocial outcomes, a comprehensive health-economic evaluation will be performed.

Discussion: This paper describes the implementation and evaluation of two family-based intervention programs for Children Affected by Rare Disease and their Family's Network (CARE-FAM-NET) in German standard care. A methodologically challenging study design is used to reflect the complexity of the actual medical care situation. This trial could be an important contribution to the improvement of care for this highly burdened group.

Trial registration: German Clinical Trials Register: DRKS00015859 (registered 18 December 2018) and ClinicalTrials.gov : NCT04339465 (registered 8 April 2020). Protocol Version: 15 August 2020 (Version 6.1). Trial status: Recruitment started on 1 January 2019 and will be completed on 31 March 2021.

Keywords: Family intervention; Internet-based intervention; Mental health; Randomized controlled trial; Rare diseases.

PubMed Disclaimer

Conflict of interest statement

All authors declare that there are no competing interests.

Figures

Fig. 1
Fig. 1
Study design

Similar articles

Cited by

References

    1. European Commission. Rare diseases [Internet]. 2005. Available from: http://europa.eu.int/comm/health/ph_threats/non_com/rare_diseases_en.htm.... European Commission, European Union.
    1. Wetterauer B, Schuster R. Seltene Krankheiten - Probleme, Stand und Entwicklung der nationalen und europäischen Forschungsförderung [Rare diseases. Funding programs in Germany and Europe] Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz. 2008;51(5):519–528. doi: 10.1007/s00103-008-0524-7. - DOI - PubMed
    1. EURORDIS. Rare diseases: understanding this public health priority [Internet]. 2005. Available from: http://beta.eurordis.org/IMG/pdf/princeps_document-EN.pdf. Accessed 08 October 2019.
    1. Frank M, Eidt-Koch D, Aumann I, Reimann A, Wagner TOF, von der Schulenburg JM. Maßnahmen zur Verbesserung der gesundheitlichen Situation von Menschen mit seltenen Erkrankungen in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(10):1216–1223. doi: 10.1007/s00103-014-2040-2. - DOI - PubMed
    1. Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet. 2010;152A(5):1136–1156. doi: 10.1002/ajmg.a.33380. - DOI - PMC - PubMed

Publication types

Associated data